COLLEGEVILLE, Penn--Rhône-Poulenc Rorer Inc.'s Taxotere
(docetaxel) is now available for treatment of patients with locally
advanced or metastatic breast cancer that has progressed during
anthracycline-based therapy or relapsed during anthracycline-based
In clinical studies, Taxotere has shown the highest response rate
ever (47%) for a single agent in this patient population at a
dose of 100 mg/m² given IV over 1 hour every 3 weeks, "a
very convenient administration schedule," Howard A. Burris
III, MD, of the Cancer Therapy and Research Center, San Antonio,
said at a teleconference held to launch the new product.
Dr. Burris noted that "with a drug with this much impact
in shrinking tumors in the advanced stage, the hope is that we
will eventually be able to bring it into stage I, II, and III
treatment, and those clinical trials are ongoing."
The pivotal Taxotere trials were reported in this publication
in Nov 1995, page 1, and June 1996, page 16.